Prodige/ACCORD 12/0450 trial
Oxaliaplatin 50mg/m2 x 5
Capecitabine 800mg/m2
*
50.4Gy CRT
45 Gy CRT
N=598
S
Centre policy
Primary end point- pCR 11% - 20% 85% power
Staging :- Evaluated by TRUS and/or MRI